Drug Trial Radar · NCT04230148
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Feb 11, 2022
Primary completion
Mar 27, 2026
Study completion Mar 27, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6 years of age).
Conditions
- Fascioliasis
Interventions
Egaten (Triclabendazole) 250 mg tabletsDrug
Egaten 250 mg scored tablets for oral use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Alexandria, Egypt
Novartis Investigative Site
Cairo, Egypt, Egypt
Novartis Investigative Site
Cusco, Peru
Novartis Investigative Site
San Martín de Porres, Lima region, Peru
Novartis Investigative Site
Sur, Turkey (Türkiye)
Novartis Investigative Site
Van, Turkey (Türkiye)
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye)
Novartis Investigative Site
Gaziantep, Sehitkamil, Turkey (Türkiye)
Novartis Investigative Site
Qui Nhon, Binh Dinh, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.